Are we ready for therapeutic drug monitoring of biologic therapeutics?

Arthritis Research and Therapy

Volumn 13, Issue 4, 2011, Pages

  Krieckaert, Charlotte L M ^a   Lems, Willem F ^a,b  

^a Jan Van Breemen Research Institute/Reade   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTIRHEUMATIC AGENT; AZATHIOPRINE; DRUG ANTIBODY; ETANERCEPT; INFLIXIMAB; METHOTREXATE; PREDNISONE; TUMOR NECROSIS FACTOR; ANTIBODY; MONOCLONAL ANTIBODY;

ANKYLOSING SPONDYLITIS; ANTIBODY DETECTION; BINDING SITE; DRUG BLOOD LEVEL; DRUG MONITORING; EDITORIAL; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; THROMBOEMBOLISM; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; BLOOD; IMMUNOLOGY; NOTE; SPONDYLARTHRITIS;

ANTIBODIES; ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; HUMANS; SPONDYLARTHRITIS;

EID: 79960944225     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar3395     Document Type: Editorial

References (11)

1. Ducourau E, Mulleman D, Paintaud G, Chu Miow Lin D, Lauféron F, Ternant D, Watier H, Goupille P. Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases. Arthritis Res Ther 2011, 13:R105. 10.1186/ar3386, 21708018.
2. Bartelds GM, Krieckaert CL, Nurmohamed MT, van Schouwenburg PA, Lems WF, Twisk JW, Dijkmans BA, Aarden L, Wolbink GJ. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA 2011, 305:1460-1468. 10.1001/jama.2011.406, 21486979.
3. Baert F, Noman M, Vermeire S, van Assche G, D'Haens G, Carbonez A, Rutgeerts P. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003, 348:601-608. 10.1056/NEJMoa020888, 12584368.
4. Karmiris K, Paintaund G, Noman M, Magdelaine-Beuzelin C, Ferrante M, Degenne D, Claes K, Coopman T, Van Schuerbeek N, Van Assche G, Vermeire S, Rutgeerts P. Influence of trough serum levels and immumogenicity on long-term outcome of adalimumab therapy in Crohn's disease. Gastroenterology 2009, 137:1628-1640. 10.1053/j.gastro.2009.07.062, 19664627.
5. Pascual-Salcedo D, Plasencia C, Ramiro S, Nuño L, Bonilla G, Nagore D, Ruiz Del Agua A, Martínez A, Aarden L, Martín-Mola E, Balsa A. Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis. Rheumatology (Oxford) 2011, 50:1445-1452.
6. Korswagen LA, Bartelds GM, Krieckaert CL, Turkstra F, Nurmohamed MT, van Schaardenburg D, Wijbrandts CA, Tak PP, Lems WF, Dijkmans BA, van Vugt RM, Wolbink GJ. Venous and arterial thromboembolic events in adalimumab-treated patients with antiadalimumab antibodies: a case series and cohort study. Arthritis Rheum 2011, 63:877-883. 10.1002/art.30209, 21452312.
7. Wolbink GJ, Aarden LA, Dijkmans BA. Dealing with immunogenicity of biologicals: assessment and clinical relevance. Curr Opin Rheumatol 2009, 21:211-215. 10.1097/BOR.0b013e328329ed8b, 19399992.
8. Krieckaert CL, Bartelds GM, Lems WF, Wolbink GJ. The effect of immunomodulators on the immunogenicity of TNF-blocking therapeutic monoclonal antibodies: a review. Arthritis Res Ther 2010, 12:217. 10.1186/ar3147, 2991013, 21029481.
9. Dore RK, Mathews S, Schechtman J, Surbeck W, Mandel D, Patel A, Zhou L, Peloso P. The immunogenicity, safety, and efficacy of etanercept liquid administered once weekly in patients with rheumatoid arthritis. Clin Exp Rheumatol 2007, 25:40-46.
10. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, Jackson CG, Lange M, Burge DJ. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999, 340:253-259. 10.1056/NEJM199901283400401, 9920948.
11. Jamnitski A, Hart M, Nurmohamed MT, Krieckaert C, Dijkmans BA, Aarden L, Voskuyl AE, Wolbink GJ. Patients non-responding to etanercept obtain lower etanercept concentrations compared to responding patients [abstract]. Ann Rheum Dis 2011, 70(Suppl 3):119.